Daxor continues development of BVA-100:
This article was originally published in Clinica
Daxor (US) is to continue development of its BVA-100 blood volume analyser now that production of its albumin I-131 isotope has been approved by the US FDA. A suspended 510(k) application for the BVA-100 will now continue after eight years waiting for approval of the isotope. Iodine-131 is essential for measuring blood volume and will be part of the test kit for the New York-based company's analyser used during surgery. The albumin I-131 will be manufactured by Texas-based Iso-Tex Diagnostics.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.